<?xml version="1.0" encoding="UTF-8"?>
<p>Omeprazole and other proton pump inhibitors have been found to increase the activity of anti-cancer drugs including the nucleoside analogue 5-fluorouracil (
 <xref rid="B26" ref-type="bibr">Luciani et al., 2004</xref>; 
 <xref rid="B15" ref-type="bibr">Ikemura et al., 2017</xref>). Proton pump inhibitors are the most frequently prescribed drugs for the treatment and prophylaxis of gastroesophageal reflux as well as of gastric and duodenal ulcers that are associated with hyper-acidic states. Since they are known to be well-tolerated, they were suggested as repositioning candidates for the use as part of anti-cancer therapies (
 <xref rid="B26" ref-type="bibr">Luciani et al., 2004</xref>; 
 <xref rid="B15" ref-type="bibr">Ikemura et al., 2017</xref>).
</p>
